CFM
ATXS

Catalyst Funds Management’s Astria Therapeutics ATXS Stock Holding History

Catalyst Funds Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,700
Closed -$40.7K – 395
2024
Q3 		$40.7K Buy
3,700
+3,400
+1,133% +$37.8K 0.01% 875
2024
Q2 		$2.73K Sell
300
-3,875
-93% -$37.8K ﹤0.01% 1111
2024
Q1 		$58.8K Buy
+4,175
New +$52K 0.02% 519

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Catalyst Funds Management's ATXS Position: Q4 2024 in Review

Catalyst Funds Management sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 3,700 shares — an estimated $40.7K sold.

Catalyst Funds Management first reported a position in ATXS in Q1 2024 and held it in 3 quarters. The position peaked at $58.8K in Q1 2024. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

  • Catalyst Funds Management reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 3,700 Astria Therapeutics shares in Q4 2024, an estimated $40.7K.
  • Catalyst Funds Management first reported a position in Astria Therapeutics in Q1 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Astria Therapeutics position peaked at $58.8K in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.